natgillin/translations-raw huggingface dataset:
Removal of the solvent at reduced pressure yielded an oil which, when purified by chromatography on silica gel (ethyl acetate/methanol gradient: 8:2/6:4), yielded 186 mg of product (yield: 81.3%) which was subsequently chlorhydrated to obtain the title compound. 
Uklanjanje otapala na sniženom tlakom dalo je ulje koje je, nakon što je pročišćeno kromatografijom na silikagelu (etil acetat/metanol gradijent: 8:2/6:4), dalo 186 mg produkta (prinos: 81,3 %) koje ne nakon toga klorinirano da bi se dobio spoj iz naslova.
The liquid composition as claimed in claim 30, wherein said composition is provided in a dose volume of about 1.5 ml. 
Tekući pripravak u skladu s patentnim zahtjevom 30, naznačen time što se navedeni pripravak daje u volumnoj dozi od otprilike 1,5 ml.
A rodent, comprising a replacement of a genomic DNA of a rodent IL-4Ra gene at an endogenous rodent IL-4Ra locus with a human genomic DNA of a human IL-4Ra gene to form a humanized IL-4Ra gene, wherein the genomic DNA of the rodent IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the rodent IL-4Ra gene, and the human genomic DNA of the human IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Ra gene; wherein the humanized IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Ra gene and exons 6-9 of the rodent IL-4Ra gene, and the human genomic DNA present in the humanized IL-4Ra gene begins with the ATG initiation codon in exon 1 of the human IL-4Ra gene; and wherein expression of the humanized IL-4Ra gene is under control of the rodent IL-4Ra promoter at the endogenous rodent IL-4Ra locus, wherein the rodent is a mouse or a rat. 
HR P20180242 T1 PATENTNI ZAHTJEVI Glodavac, naznačen time što sadrži zamjenu genomskog fragmenta gena za glodavački IL-4Ra na lokusu za endogeni glodavački IL-4Ra genomskim fragmentom gena za ljudski ILA-Ra kako bi se dobilo gen za humanizirani IL-4Ra koji sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, te kodirajuće egzone 6-9 gena za glodavački IL-4Ra, gdje genomski fragment gena za glodavački IL-4Ra sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za glodavački IL-4Ra, a genomski fragment gena za ljudski IL-4Ro sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Roa, te gdje je eksprimiranje gena za humanizirani IL-4Ra pod kontrolom regulacijskih elemenata glodavačkog IL-4Ra. na lokusu za endogeni glodavački IL-4Ra.
The medicament for use according to any one of claim 1 or claims 3-8 for use in reducing frequency of relapses in a human patient suffering from relapsing-remitting multiple sclerosis. 
Lijek za uporabu prema bilo kojem od patentnog zahtjeva 1 ili patentnih zahtjeva 3-8, naznačen time, da jest za uporabu u smanjivanju učestalosti relapsa kod pacijenta koji pati od relapsno remitirajuće multiple skleroze.
This combined blend was added to the fluidization pan and the drug solution was adsorbed on it by using Fluid bed processor (top spray process). 
Ova stopljena mješavina dodana je u fluidizacijsku posudu te je otopina lijeka adsorbirana na nj rabeći Fluid podloga procesor (top spray postupak).
The first antigen binding protein according to claim 1 that competes for binding to the extracellular portion of human c-fms with a second antigen binding protein, wherein said second antigen binding protein is an antibody comprising complementarity determining regions (CDRs) CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3, wherein said CDRs comprise the amino acid sequences as set forth below: 
HR P20171741 T1 HR P20171741 T1 PATENTNI ZAHTJEVI 1. - Protutijelo, naznačeno time što se bira iz skupine koju čine protutijelo koje sadrži područja za određivanje komplementarnosti (CDR) CDRH1, CDRH2, CDRH3, CDRLI, CDRL2, te CDRL3, gdje navedeni CDR-i imaju aminokiselinske sljedove kao što su iznijeti niže:
X is O, S, S(O) or S(O)2; is hydrogen or methyl; is hydrogen, methyl or ethyl, or forms a double bond, which links the carbon atom, to which R6 is attached, with the adjacent carbon atom of R7 or R8; 
je vodik, metil, etil, n-propil, izo-propil, halometil, haloetil, halogen, vinil, etilnil, metoksi, etoksi, halometoksi ili haloetoksi; X je O, S, S(O) ili S(O)2; R5 je vodik ili metil; R6 je vodik, metil ili etil, ili tvori dvostruku vezu, koja veže atom ugljika, na koji je R6priključen, sa susjednim atomom ugljika od R7 ili R8;
An irrelevant antibody was included as a negative control. 
Kao negativna kontrola uključeno je irelevanino protutijelo.
From the sole 2 there protrudes, from the area of the forefoot and approximately up to the area, i.e. 
Od potplata 2, iz područja prednjeg dijela stopala i približno sve do površinc, tj.
Use of a multi-layer polymeric material produced as a blown film with no subsequent lamination step to manufacture a collapsible tube container comprising a side-seam weld or join, wherein the multi-layer polymeric material comprises a thickness of between 150 and 350 microns, more preferably of between 200 and 300 microns. 
Upotreba puhanog filma višeslojnog polimernog materijala za proizvodnju fleksibilne ambalažne tube sa bočnim sučeonim šavom ili spojem, naznačena time što debljina višeslojnog polimernog materijala iznosi od 150 um do 350 um, optimalno od 200 um do 300 um.
The Ra score was 10.96±SD 2.58 at baseline, 9.46±2.08 after 14 days and 8.99±1.72 after 28 days on the nails treated with the composition according to Example 1. 
Vrijednost Ra na noktima tretiranim s pripravkom prema Primjeru 1 bila je 10,96 + SD 2,58 na početku tretmana, 9,46 + 2,08 nakon 14 dana i 8,99 + 1,72 nakon 28 dana.
The compound or pharmaceutical composition for use of claim 15, wherein the disorder is MPGN II. 
Spoj ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 15, naznačeni time što je poremećaj MPGN II.
In this way there will be obtained foams which in the humid state will have a density of 50-120 kg/m3 and in the dry state will have a density of 10-30 kg/m3. 
Na taj način dobivaju se pjene, koje imaju u vlažnom stanju gustoću od 50 do 120 ke/m* te u suhom stanju od 10 do 50 kg/m* .Potpuno stvrdnuće i posušenje izvrši se u ovisnosti od uvjeta temperature, prozračavanja i propustnosti stijena u 20 do 30 dana.
A nucleic acid molecule or a set of nucleic acid molecules encoding the compound of any one of claims 1 to 5 or the conjugate of claim 8 or 9 or a complement thereof. 
Molekula nukleinske kiseline ili set molekula nukleinske kiseline koji šifrira spoj prema bilo kojem od zahtjeva 1 do 3 ili konjugat prema zahtjevu 6 ili 7 ili njihov komplement.
represents one of the following groups: 
Datum objave europskog patenta:
G is phenyl optionally substituted by one to four R9 groups or a 5-6 membered heteroaryl optionally substituted by a halogen; 
A je [image], G je fenil opcijski supstituiran jednom do četiri R9 skupine ili 5-6-člani heteroaril opcijski supstituiran halogenom;
The composition for use according to claim 1, wherein the antibiotic is thiamphenicol, the anti-fungal is terbinafine and the NSAID is diclofenac. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je antibiotik tiamfenikol, antimikotik je terbinafin, a NSAID je diklofenak.
There is provided a compound of formula (I): 
PATENTNI ZAHTJEVI 1. Spoj formule (I):
The pharmaceutical composition according to claim 1, 2, 3 or 4 comprising an amount of 5 to 50 mg of the glucopyranosyl-substituted benzene derivative and an amount of 0.5 to 10 mg of the DPP IV inhibitor. 
Farmaceutski sastav prema zahtjevu 1, 2, 3 ili 4, naznačen time, da sadrži količinu od 5 do 50 mg derivata benzena supstituiranog glukopiranozilom 1 količinu od 0,5 do 10 mg DPP IV-inhibitora.
An inhalable pharmaceutical solution aerosol for use as claimed in claim 1, consisting essentially of beclometasone dipropionate, ethanol and a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof. 
Farmaceutska otopina aerosola za inhalaciju u skladu s patentnim zahtjevom 1, sastoji se u osnovi od beklometazom dipropionata, etanola 1 propelanta odabranog između 1,1,1,2-tetrafluoroetana, 1,1,1,2,3,3,3-heptafluoropropana i njihove smjese.
Fuel supply arrangement according to claim 7, characterized in that said fuel pump (4.3; 4.3') is arranged to supply fuel to said buffer tank (4.2) at a first volumetric flow rate, said first volumetric flow rate being at least equal to, preferably larger than, a second volumetric flow rate to be supplied to said engine (2). 
Uređaj za snabdijevanje gorivom u skladu s patentnim zahtjevom 5, naznačen time što je navedena pumpa za gorivo (4.3; 4.3 ́) postavljena da snabdijeva gorivom navedeni pomoćni spremnik (4.2) s prvim volumnim protokom, pri čemu je prvi volumni protok najmanje jednak drugom volumnom protoku s kojim se treba snabdijevati navedeni motor (2), a poželjno je da je veći od drugog volumnog protoka.
The isolated IL-23p19 antibody of embodiment 5, further comprising at least one human framework region adjacent to the at least one complementarity determining region. 
Izolirano IL-23p19 antitijelo iz zahtjeva 1, naznačeno time da dalje sadrži najmanje jednu ljudsku okvirnu regiju susjednu sa najmanje jednom komplementarnom određujućom regijom.
The method of anyone of claims 1 to 13 in which the methionine derivative, N-acetylmethionine is transformed into methionine by deacylation, before methionine is recovered. 
Metoda iz patentnih zahtjeva 1 do 10, naznačena time da prije izoliranja metionina obuhvaća korak pretvorbe N-acetilmetionina u metionin deaciliranjem.
More preferably, the hop containing beverage is beer, malt liquor, porter, shandy, or another beverage made from or containing fermented extracts of malt. 
Poželjnije, piće koje sadržava hmelj je pivo, alkoholno piće na bazi slada, tamno pivo (porter), smjesa piva i đumbirovog piva ili limunade (shandy), ili drugo piće koje se proizvodi iz ili sadržava fermentirane ekstrakte slada.
The present invention relates to a novel compound, to the process for preparing it, to pharmaceutical compositions comprising it and to its use in treating medical disorders. 
OPIS IZUMA Ovaj se izum odnosi na nove spojeve, postupka za njihovu pripravu, farmaceutske pripravke koje ih sadrže 1 njihovu upotrebu u liječenju medicinskih poremećaja.
A method of preparing a compound of formula (II): or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof; 
[image], ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (I), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese.
The compounds of the invention are those compounds of formula (I), wherein R1 and R2 represent independently hydrogen, or C1-6 alkyl, with straight or branched chain optionally substituted with one or more C1-6 alkoxycarbonyl, aryl, or (C1-6 alkoxycarbonyl)-C1-6 alkyl group, or R1 and R may form a heterocyclic ring with the adjacent nitrogen atom, which may be saturated or unsaturated optionally substituted monocyclic or bicyclic ring, which may contain further heteroatoms selected from O, N, or S, or C2-7 alkenyl with 1 to 3 double bond, or a mono-, bi- or tricyclic aryl optionally substituted with one or more C1-6 alkoxy, trifluoro C1-6 alkoxy, C1-6 alkoxycarbonyl, C1-6 alkanoyl, aryl, C1-6 alkylthio, halogen or cyano, or an optionally substituted mono-, bi- or tricyclic cycloalkyl group, or aroyl group; 
R; i R2 neovisno predstavljaju vodik, ili C,.4 alkil, s ravnim ili razgranatim lancem opcijski supstituiran s jednom ili više od sljedećih skupina: C;.4 alkoksikarbonil, aril, ili (Ci.4 alkoksikarbonil)-C1.4 alkil, ili R; i R» mogu tvoriti heterociklični prsten sa susjednim atomom dušika, koji može biti zasićen ili nezasićen opcijski supstituiran monociklički ili biciklički prsten, koji može sadržavati heteroatome odabrane od O, N ili S, ili C2_7 alkenil s 1 do 3 dvostrukih veza, ili mono-, bi- ili triciklički aril opcijski supstituiran s jednom ili više od sljedećih skupina: C1.4 alkoksi, trifluoro Cig alkoksi, Cig alkoksikarbonil, C1.4 alkanoil, aril, Ci alkiltio, halogen ili cijano, ili opcijski supstituirana mono-, bi- ili triciklička cikloalkil skupina, ili aroil skupina;
The amount of emulsifier used in the present invention is present in an amount of about 0.1 to about 10% by weight, preferably about 0.5 percent to about 5 percent by weight, most preferably about 2 percent to about 4 percent by weight. 
Količina emulgatora upotrijebljenog u ovom izumu je prisutna u količini od oko 0,1 do oko 10 % po masi, poželjno oko 0,5 postotaka do oko 5 postotaka po masi, najpoželjnije oko 2 postotka do oko 4 postotka po masi.
The samples 3A and C were "smoked" on a conventional cigarette smoking machine using the conditions of a 35 ml puff volume, a two second puff duration, and a 30 second puff frequency, for ten puffs. 
3es., HR P950147 B1 ml, za vrijeme trajanja dima od dvije sekunde, i za učestalost uvlačenja dimova od 30 sekundi, za deset dimova.
The method of claim 21, wherein the compound has a structure which is selected from the group consisting of The method of claim 1, wherein the disease is a member selected from Crohn's disease, ulcerative colitis, arthritis, rheumatoid arthritis, psoriasis, Alzheimer's disease, Parkinson disease, atopic dermatitis, and actinic keratosis. 
Spoj prema bilo kojem od zahtjeva 1 do 3, farmaceutska formulacija prema zahtjevu 4 ili topikalna farmaceutska formulacija prema zahtjevu 5 za uporabu u liječenju ili sprečavanju stanja koje se bira iz grupe koja se sastoji od: Crohnove bolesti, ulceroznog kolitisa, artritisa, reumatoidnog artritisa, psorijaze, Alzheimerove bolesti, Parkinsonove bolesti i atopijskog dermatitisa.
Aspect 9. The use according to aspect 8, wherein the hydrophilic gelling agent is chosen from glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbopol® polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što pripravak dodatno sadrži najmanje jedno hidrofilno sredstvo za želiranje, poput glukoze, modificiranog škroba, metilceluloze, karboksimetilceluloze, propilceluloze, hidroksipropilceluloze, Carbopol& polimera, alginske kiseline, natrijevog alginata, kalijevog alginata, amonijevog alginata, kalcijevog alginata, agara, karagenana, karuba gume, pektina, te želatine.
The antibody which binds to human PD-1 of claim 6, wherein the heavy chain comprises amino acid residues 20 to 466 of SEQ ID NO: 31 and the light chain comprises amino acid residues 20 to 237 of SEQ ID NO: 36. 
7. Antitijelo prema patentnom zahtjevu 6, naznačeno time što teški lanac sadrži aminokiselinske ostatke 20 do 466 iz sekv. id. br.: 31 1 lagani lanac sadrži aminokiselinske ostatke 20 do 237 iz sekv.
Nephrol., 2000, 32,73), atherosclerosis and restenosis (Bokemeyer et al., Kidney Int., 2000, 58, 549). 
Nephrol., 2000, 32,73), aterosklerozi i restenozi (Bokemeyer i sur., Kidney Int., 2000, 58, 549).
The selective inhibitor of Aurora A kinase for use of any of claims 1-3, wherein the proliferative disorder is pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, brain tumor, bone cancer, or soft tissue sarcoma. 
Spoj prema bilo kojem od patentnih zahtjeva 1-7 za upotrebu u liječenju poremećaja posredovanog preko Aurora kinaze. Spoj prema patentnom zahtjevu 12, naznačen time što, poremećaj posredovan preko Aurora kinaze, je kancer. Spoj prema patentnom zahtjevu 13, naznačen time što je kancer izabran iz grupe koju čine kolorektalni kancer, kancer jajnika, kancer dojke, kancer želudca, kancer prostate i kancer pankreasa.
A method for reducing alcohol consumption in a patient with alcohol dependence comprising, administering a therapeutically effective amount of nalmefene to the patient, wherein the patient has a drinking risk level corresponding to a mean daily consumption of >60 g of alcohol for men and >40 g of alcohol for women. 
gdje navedeni pacijent održava DRL koji odgovara potrošnji >60 g dnevno čistog alkohola za muškarce i >40 g dnevno za žene nakon perioda praćenja koji slijedi za početnom procjenom; i gdje je navedeni period praćenja koji slijedi za početnom procjenom 1-2 tjedna, primjerice otprilike 2 tjedna.
reacting the intermediate of formula (XVII) with O-(tetrahydro-2 H -pyran-2-yl)-hydroxylamine, in the presence of an appropriate coupling reagents. 
reakciju intermedijera formule (XVII) s O-(tetrahidro-2H-piran-2-il)-hidroksilaminom, u prisutnosti odgovarajućih reagensa za spajanje. [image]
Decoder according to claim 1, characterised in that said prefixed cadence (T3) of the maintenance pulses is 1350µs 
Dekoder u skladu s patentnim zahtjevom 1, naznačen time, što prefiksirana kadenca (T3) održavanja impulsa je 1350 us.
The composition of claim 19, further comprising at least one compound or agent selected from a detectable label, keyhole limpet hemocyanin, tetanus toxoid or a toxoid derived from other pathogenic bacteria, serum albumins, bovine serum albumin, an immunoglobulin molecule or fragment thereof, thyroglobulin, ovoglobulin, a universal T cell epitope, a cytokine, a chemokine, IL-1 a, IL-, IL-2, IL-10, IFN-Y, GM-CSF, MIP1 a, MIP1 B, and RANTES. 
Pripravak iz patentnog zahtjeva 19, naznačeno time da dalje sadrži najmanje jedan spoj ili sredstvo odabrano od biljega koji se može detektirati, hemocijanina iz školjke Megathura crenulata, toksoida tetanusa ili toksoida izvedenog od drugih patogenih bakterija, albumina iz seruma, albumina iz goveđeg seruma, imunoglobulinske molekule ili njihovog fragmenta, tiroglobulina, ovoglobulina, univerzalnog epitopa T-stanice, citokina, kemokina, IL-1 a, IL-, IL-2, IL-10, IFN-Y, GM-CSF, MIP1 a, MIP1 B, te RANTES.
The pharmaceutical composition for use according to claim 16, wherein the disorder is depression. 
Farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 15, pri čemu je poremećaj depresija.
An antigen binding protein that binds human c-fms, wherein said antigen binding protein is selected from the group consisting of: 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 17, naznačeno time što se bolest kostiju bira iz skupine koju čine:
wherein m is 1; is selected from the group consisting of hydroxy, hydroxymethyl, amino, acylamino, acetylamino and methylamino; and 
(Rom pri čemu m je 1 i Rs je izabran iz skupine koju čine hidroksi, hidroksimetil, amino, acilamino, acetilamino i metilamino.
The mentioned motor block parts (the motor 12, the gear box 13, the motor block support 14, the spindle 15 and the shaft 16) are actually fixed free in rotation to the main frame 26 by the motor block bearing axis 41 (see e.g. Figure 3). 
Navedeni dijelovi motornog bloka (motor 12, zupčani prijenosnik 13, oslonac bloka motora 14, vreteno 15 i osovina 16) su radno pričvršćeni na glavni okvir 26 i to na takav način da mogu slobodno rotirati oko ležajne osovine 41 bloka motora (vidi, na primjer, sliku 3).
The compound of claim 1 wherein R2 is a substituent selected from the group consisting of hydrogen and C1-4alkyl. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što je glidant izabran iz grupe koju čine talk, kukuruzni škrob i silika.
G2, G3 and G4 are independently selected from CH and N; with the proviso that at least 1 of G3 and G4 is N; with the proviso that G1 and G2 are not both N; 
, G3 i G4 se neovisno biraju od CH i N; pod uvjetom da najmanje 1 od G3 i G4 je N; pod uvjetom da oba G1 i G2 nisu N;
A common type of home injuries takes place when people use power network supplied devices while taking a bath or near a pool. 
Čest slučaj ozljeda u domaćinstvu se događa kada ljudi koriste uređaje napajane iz električne mreže za vrijeme kupanja ili blizu bazena.
a nucleotide sequence represented by SEQ ID NO: 43; 
D nukleotidni slijed predstavljen kao SEQ ID NO: 43.
For PPARa, a GAL4 chimeric system is the standard CTF assay performed. 
Za PPARa GALA kimerni sustav provedeno je standardno CTF ispitivanje.
In another example, the method may further comprise: determining with the processor mechanism evidence of at least a third user mark in the detected third user marking cell based at least in part upon a degree of brightness similarity between: (a) at least a portion of the electronic image surrounding the indicium bounding the third user marking cell; and (b) at least a portion of the electronic image included inside the indicium bounding the third user marking cell. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što dodatno uključuje: određivanje procesorskim mehanizmom dokaza o u najmanju ruku trećoj korisničkoj oznaci u detektiranoj trećoj ćeliji za korisničku oznaku na temelju u najmanju ruku dijelom stupnja sličnosti svjetline između: (a) u najmanju ruku dijela elektronske slike koji okružuje bilješku koja omeđuje treću ćeliju za korisničku oznaku; i (b) u najmanju ruku dijela elektronske slike koji se nalazi unutar bilješke koja omeđuje treću ćeliju za korisničku oznaku.
according to the standardized mobile communication technology, or according to an alternative standardized mobile communication technology, wherein during a second time interval, the antenna device is used for transmitting and/or receiving radio frequency signals on the second carrier frequency (120) according to a further mobile communication technology, wherein the first time interval and the second time interval are alternating, and wherein the second carrier frequency (120) is a frequency in a frequency range out of the following: 
- prema standardiziranoj mobilnoj komunikacijskoj tehnologiji, ili - prema alternativnoj standardiziranoj mobilnoj komunikacijskoj tehnologiji, pri čemu se za vrijeme drugog vremenskog intervala, antenski uređaj koristi za predaju iili prijem radio frekventnih signala na drugoj nosećoj frekvenciji (120) u skladu sa slijedećom mobilnom komunikacijskom tehnologijom, pri čemu su prvi vremenski interval 1 drugi vremenski interval naizmjenični, 1 pri čemu je druga noseća frekvencija (120) frekvencija u frekventnom opsegu između slijedećih:
B—at least one high-boiling co-solvent at a concentration from 2% by weight to 20% by weight selected from the group, consisting of high-boiling glycols, glycol ethers and amine compounds, wherein the high-boiling co-solvent has a boiling point of at least 100° C.; and C—at least one pH-active agent at a concentration from 0.01% by weight to 5% by weight selected from the group, consisting of acid compounds or selected from the group, consisting of hydroxide compounds. 
Sastav za skidanje u skladu sa zahtjevom 1, naznačen time da B- najmanje jedno suotapalo visokog vrelišta odabrano je iz skupine, koja se sastoji od aminskih spojeva, pri čemu suotapalo s visokim vrelištem ima vrelište od najmanje 100°C; i C- najmanje jedno pH aktivno sredstvo odabrano iz skupine, koja se sastoji od kiselinskih spojeva ili odabrano iz skupine, koja se sastoji od hidroksidnih spojeva.
a flying shear at an exit end of said rolling mill; 
leteće škare (13) na izlazu iz valjaonice (11);
Very particularly preferred veneers have a humidity content between 5 and 20 %. 
Naročito vrlo poželjni furniri imaju sadržaj vlage između 5 i 20 %.
• y is an integer from 1 to 20 and can also be 0; 
• y je cijeli broj od 1 do 20, a također može biti i 0;
The kit according to claim 14, wherein the TNFa inhibitor is an anti-TNFa antibody. 
Pribor u skladu s patentnim zahtjevom 14, naznačen time, da je TNFqa inhibitor protu-TNFa protutijelo.
The mineral composition according to claim 1, wherein the mineral powder (c) has a thermal conductivity (λ) at 20° C. of between 20 and 500 W/(m·K). 
od 0,5 do 4,8%, poželjno od 1,5 do 4,5%, a posebno od 2 do 4,5% po masi mineralnog praha koji ima toplinsku vodljivost (λ) na 20°C između 20 i 500 W/(m.